文献速递前列腺癌

转移性去势抵抗性前列腺癌患者长期达罗他胺治疗的安全性与耐受性

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-10-26

该汇总分析基于1/2期研究的个体患者数据,描述13例转移性去势抵抗性前列腺癌患者接受达罗他胺中位38个月治疗的不良事件。所有患者均报告不良事件(多为1/2级),最常见为腹泻、腹痛和恶心;6例报告严重不良事件(均与达罗他胺无关),5例治疗相关不良事件均为1级。结论为长期达罗他胺治疗耐受性良好,未观察到新的安全性信号。

要点

  • 13例转移性去势抵抗性前列腺癌患者接受达罗他胺中位38个月治疗。
  • 所有患者报告不良事件,多为1/2级,最常见为腹泻、腹痛和恶心。
  • 6例报告严重不良事件(均与达罗他胺无关),治疗相关不良事件均为1级。

核心结论

  • 长期达罗他胺治疗耐受性良好,未观察到新的安全性信号,与既往报告一致。

研究设计与样本

  • 基于1/2期研究个体患者数据的汇总分析,纳入接受达罗他胺中位38个月治疗的转移性去势抵抗性前列腺癌患者13例。

主要发现

  • 所有患者均报告治疗中出现的不良事件,多为1/2级。
  • 最常见的治疗中出现的不良事件为腹泻、腹痛和恶心。
  • 6例患者报告严重治疗中出现的不良事件,均与达罗他胺无关。
  • 5例治疗相关治疗中出现的不良事件均为1级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available. METHODS: Treatment-emergent adverse events (TEAEs) for patients receiving darolutamide for a median of 38 months (n = 13) are described in this pooled analysis of individual patient data from phase 1/2 studies. RESULTS: All patients reported TEAEs (mostly grade 1/2). The most common TEAEs were diarrhea, abdominal pain, and nausea. Serious TEAEs were reported in six patients (none related to darolutamide). All treatment-related TEAEs (n = 5) were grade 1. CONCLUSIONS: Long-term darolutamide treatment was well tolerated; no new safety signals observed. In patients with mCRPC, long-term darolutamide treatment was well tolerated and no new safety signals were observed. These findings are consistent with previous reports, demonstrating a favorable safety and tolerability profile of darolutamide.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Jones RH, Fizazi K, James ND, et al. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 37884613. doi:10.1038/s41391-023-00740-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。